Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Fifth Third Bancorp Raises Position in Charles River Laboratories ...

AI-generated analysis

📈 Fifth Third Bancorp raised its CRL position by 51.2% in Q1, adding 6,002 shares to a total holding of 17,733 shares valued at $3.059 million.

🏦 Invesco Ltd. increased its stake by 115.8% in Q4, now owning 2.696 million shares worth approximately $537.8 million.

🚀 Victory Capital Management Inc. surged its position by nearly 10,000% in Q4, acquiring 684,586 shares valued at $137.9 million.

🇳🇴 Norges Bank initiated a new stake in CRL during the fourth quarter with a valuation of roughly $96.8 million.

💰 Ameriprise Financial Inc. raised its position by 1,491.1% in Q3, purchasing an additional 575,039 shares worth $96 million.

📉 Director James C. Foster sold 75,000 shares for $16.875 million in June, representing a 70.36% reduction in his personal holdings.

📊 Institutional investors own 98.91% of Charles River Laboratories International's outstanding stock.

🎯 Citigroup and Evercore maintain 'buy' or 'outperform' ratings with price targets around $220 per share.

⚠️ JPMorgan Chase reduced its target price to $160 and issued a 'neutral' rating on the stock.

📈 Barclays raised its price target from $210 to $220 and upgraded the rating to 'overweight'.

🏢 The company has a market capitalization of $10.59 billion with a 52-week trading range between $144.26 and $237.86.

🧬 CRL provides essential preclinical and clinical support services, including toxicology and pathology, for the pharmaceutical industry.

Bullish Signals
  • Fifth Third Bancorp significantly increased its investment in CRL by 51.2% in Q1, signaling strong institutional confidence.
  • Major hedge funds including Invesco Ltd., Victory Capital, and Ameriprise Financial have aggressively accumulated shares, with Victory Capital increasing its stake nearly 10,000%.
  • Norges Bank, a sovereign wealth fund, initiated a substantial new position valued at approximately $96.8 million.
  • Analyst consensus is 'Moderate Buy' with an average price target of $220.75, supported by recent upgrades from Barclays and Evercore.
  • The company maintains a strong balance sheet with a quick ratio of 1.03 and a current ratio of 1.36.
Risk Factors
  • Director James C. Foster sold 75,000 shares for $16.875 million in June, reducing his personal stake by over 70%.
  • JPMorgan Chase downgraded its price target to $160 and issued a 'neutral' rating, contrasting with other bullish analysts.
  • The stock trades at a negative P/E ratio of -58.49, indicating recent earnings challenges or accounting adjustments.
Full Analysis
Fifth Third Bancorp increased its stake in Charles River Laboratories International (CRL) by 51.2% during the first quarter, purchasing an additional 6,002 shares to hold a total of 17,733 shares valued at $3,059,000. This move joins a broader trend of institutional accumulation, with major entities like Invesco Ltd., Massachusetts Financial Services Co., Victory Capital Management Inc., Ameriprise Financial Inc., and Norges Bank all establishing or significantly expanding their positions in the medical research company during the fourth quarter. Analyst sentiment remains mixed but generally positive regarding CRL's long-term prospects. Major banks including Citigroup, Evercore, and Barclays have issued 'buy' or 'outperform' ratings with price targets ranging from $215 to $220 per share. However, JPMorgan Chase recently downgraded its target price to $160 with a 'neutral' rating. The consensus among eleven analysts is currently a 'Moderate Buy' with an average price target of $220.75. In insider trading news, Director James C. Foster executed a significant sale of 75,000 shares in late June under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by over 70%. Despite this insider liquidation, institutional investors collectively own 98.91% of the company's outstanding stock. Financial metrics show a market capitalization of $10.59 billion and a negative P/E ratio of -58.49, reflecting recent earnings dynamics. Charles River Laboratories International operates as a leading provider of research models and preclinical support services for the pharmaceutical and biotechnology sectors. Founded in 1947, the company offers core offerings including discovery, safety assessment, toxicology, and pathology services, alongside the supply of laboratory animals. These capabilities help clients accelerate drug development from early discovery through regulatory submission, serving a critical role in the medical device and life sciences industries.